“Medical grade” is a phrase, not a certification. It’s not defined by any regulatory agency. It’s not verified by any lab. And companies don’t need anyone’s permission to print it on a box.
THE PATH TO CLEARANCE
There are really two ways companies arrive at that decision. They can submit their product for FDA review before they ever sell anything, which means betting on a product nobody has bought yet. Or they can build a consumer following first, let real usage prove there’s a market, and only then bring their product, and related evidence, to the FDA to earn clearance. Both are legitimate strategies, and sometimes the path is predetermined for you.
Eight Sleep spent years selling a temperature-regulating mattress cover with the integrated sleep sensor technology as a wellness product, slowly amassing what’s now one of the largest sleep datasets in the world. Only after that, with customers and data already in hand, did the company file FDA applications for medical-device classifications covering sleep apnea and, separately, menopause. The goal is a device that can screen, detect, and intervene at a population scale, not just flag a risk. CEO Matteo Franceschetti says customers are effectively “sleeping on a stethoscope,” and the connected artificial intelligence system is already flagging cardiovascular patterns internally that it can’t yet disclose because the FDA hasn’t reviewed the evidence. The product came first. The proof is catching up to it.
Ozlo is running the same play. While the company launched its Sleepbuds as a consumer product, it is pursuing an FDA path for a tinnitus solution as part of a broader consumer-to-healthcare product move. The consumer business builds the real-world foundation—how people use and stick with the product—that a cleared clinical offering would stand on.
For both companies, the pursuit has become a fundraising story as much as a product one. Eight Sleep’s push toward an FDA-recognized sleep apnea indication landed alongside a jump to a $1.5 billion valuation. Ozlo earmarked part of a $12 million raise specifically for pursuing FDA clearance of its tinnitus therapy. Announcing that you’re going after FDA validation is increasingly part of how a wellness company sells itself to investors, not just to customers.
WHAT THIRD-PARTY VALIDATION BUYS YOU
A lot of consumer health technology never seeks that outside verification. Apple recently detailed a major AI expansion of its Health app, telling users that “all of our health innovations are subject to rigorous scientific validation.” That’s a real commitment, but it’s also an entirely internal one: Apple checking Apple’s own work. Google’s redesigned Health app, which absorbed Fitbit this year, shows what internal-only validation can miss: Users have reported the AI coach fabricating entire workouts, inventing a run that never happened, and logging hours with no heartbeat as sleep.
Neither of these apps required FDA review, because neither makes a diagnostic claim. The issue isn’t that companies are lying. It’s that a truly independent review gives consumers confidence that the claims have been checked and validated. And that review goes well beyond the claims themselves. Qualifying suppliers, building a quality system, weighing risk against benefit, and running ongoing checks to ensure consistency: That’s what FDA regulation requires. It isn’t designed to slow down innovation, even though the process itself can be slow. It’s designed to ensure quality and safety.
WHEN THE CATEGORY MAKES THE DECISION FOR YOU
Bobbie is a clear example of what happens when a company doesn’t get to pick its own timing. As founder and CEO Laura Modi explained on the How I Built This podcast, she launched a small 2019 pilot selling infant formula to about a hundred San Francisco Bay Area families. She positioned her product as “companion formula,” a supplement to breast milk rather than a baby’s sole source of nutrition. This placed it in a different, less restrictive regulatory category than “baby formula.” The FDA noticed, shut down the operation, and forced a national recall. Modi and her team regrouped, purchased a fully vertically integrated manufacturing facility, hired an experienced regulatory lead, and nearly two years later relaunched as properly cleared baby formula. As the new dad of a strong son with “thighs by Bobbie,” I’m glad she didn’t fold.
My company had to pursue FDA review from the start: Devices delivering UVB light therapy are regulated by the FDA, full stop. The Solius Pro went through FDA review before it was ever sold to a single customer, with no consumer data to lean on and no market yet proven. We purposely pursued an over-the-counter indication so people could buy it directly, rather than through a physician or insurer.
Customers are the real distribution channel. Even the strongest FDA indication is worth nothing if nobody uses the product. None of this means a regulator’s sign-off makes a product better than an unreviewed one, or that “medical grade” is dishonest marketing. It means the accountability is different. And when it’s our health on the line, we should be aspiring to the highest standard, not just the fastest one to market.
Chris Brooks is the chief strategy officer of Solius Labs.